FDA sees side effects with ThromboGenics' eye drug

BRUSSELS (Reuters) - ThromboGenics' main drug, the eye treatment ocriplasmin, may have a high rate of adverse side effects, the U.S. Food and Drug Administration said that in a preliminary report made available on Tuesday.

photography classes indianapolis online college music online music college